US groups renew call for expedited antibiotics pathway
This article was originally published in SRA
Executive Summary
A coalition of drug makers in the US joined the Infectious Diseases Society of America (IDSA) and several other groups in again urging US lawmakers to create an expedited pathway for the Food and Drug Administration to approve antibiotics intended to treat serious or life-threatening infections for which there are currently few or no satisfactory treatment options1,2.